Global C-MET & HGF Inhibitors Market 2024 by Manufacturers, Regions, Type and Application, Forecast to 2030

Global C-MET & HGF Inhibitors Market 2024 by Manufacturers, Regions, Type and Application, Forecast to 2030

c-Met inhibitors are a class of small molecules that inhibit the enzymatic activity of the c-Met tyrosine kinase, the receptor of hepatocyte growth factor/scatter factor (HGF/SF).

According to our (Global Info Research) latest study, the global C-MET & HGF Inhibitors market size was valued at US$ 2973 million in 2023 and is forecast to a readjusted size of USD 12720 million by 2030 with a CAGR of 23.3% during review period.

There are three kinds of C-MET / HGF Inhibitors, which are Cabozantinib, Crizotinib and Others. Cabozantinib hold the largest share of the C-MET / HGF Inhibitors market, with a revenue market share nearly 66% in 2019.

C-MET / HGF Inhibitors is sold through Hospitals and Drugs Store. The most proportion of C-MET / HGF Inhibitors is sold through Hospitals, and the market share in 2019 is about 77%.

North America is the largest consumption place, with a consumption market share nearly 60% in 2019. Following North America, Europe is the second largest consumption place with the consumption market share of about 34%.

Shandong Exelixis, Ipsen, Pfizer, etc. are the leader of the industry, and top 3 players hold about 100% revenue market share.

This report is a detailed and comprehensive analysis for global C-MET & HGF Inhibitors market. Both quantitative and qualitative analyses are presented by manufacturers, by region & country, by Type and by Application. As the market is constantly changing, this report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many markets. Company profiles and product examples of selected competitors, along with market share estimates of some of the selected leaders for the year 2024, are provided.

Key Features:

Global C-MET & HGF Inhibitors market size and forecasts, in consumption value ($ Million), sales quantity (K Units), and average selling prices (US$/Unit), 2019-2030

Global C-MET & HGF Inhibitors market size and forecasts by region and country, in consumption value ($ Million), sales quantity (K Units), and average selling prices (US$/Unit), 2019-2030

Global C-MET & HGF Inhibitors market size and forecasts, by Type and by Application, in consumption value ($ Million), sales quantity (K Units), and average selling prices (US$/Unit), 2019-2030

Global C-MET & HGF Inhibitors market shares of main players, shipments in revenue ($ Million), sales quantity (K Units), and ASP (US$/Unit), 2019-2024

The Primary Objectives in This Report Are:

To determine the size of the total market opportunity of global and key countries

To assess the growth potential for C-MET & HGF Inhibitors

To forecast future growth in each product and end-use market

To assess competitive factors affecting the marketplace

This report profiles key players in the global C-MET & HGF Inhibitors market based on the following parameters - company overview, sales quantity, revenue, price, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Exelixis, Ipsen, Pfizer, Novartis, Takeda, Merck KGaA, Merck, Daiichi Sankyo, GSK, Bristol-Myers Squibb(BMS), etc.

This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.

Market Segmentation

C-MET & HGF Inhibitors market is split by Type and by Application. For the period 2019-2030, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of volume and value. This analysis can help you expand your business by targeting qualified niche markets.

Market segment by Type
Cabozantinib
Crizotinib
Others

Market segment by Application
Hospital
Drug Store

Major players covered
Exelixis
Ipsen
Pfizer
Novartis
Takeda
Merck KGaA
Merck
Daiichi Sankyo
GSK
Bristol-Myers Squibb(BMS)
Roche
AVEO Pharmaceuticals
Amgen
AstraZeneca
Mirati Therapeutics
Eli Lilly
Johnson & Johnson
Eisai
Hutchison MediPharma
Kringle Pharmaceuticals

Market segment by region, regional analysis covers

North America (United States, Canada, and Mexico)

Europe (Germany, France, United Kingdom, Russia, Italy, and Rest of Europe)

Asia-Pacific (China, Japan, Korea, India, Southeast Asia, and Australia)

South America (Brazil, Argentina, Colombia, and Rest of South America)

Middle East & Africa (Saudi Arabia, UAE, Egypt, South Africa, and Rest of Middle East & Africa)

The content of the study subjects, includes a total of 15 chapters:

Chapter 1, to describe C-MET & HGF Inhibitors product scope, market overview, market estimation caveats and base year.

Chapter 2, to profile the top manufacturers of C-MET & HGF Inhibitors, with price, sales quantity, revenue, and global market share of C-MET & HGF Inhibitors from 2019 to 2024.

Chapter 3, the C-MET & HGF Inhibitors competitive situation, sales quantity, revenue, and global market share of top manufacturers are analyzed emphatically by landscape contrast.

Chapter 4, the C-MET & HGF Inhibitors breakdown data are shown at the regional level, to show the sales quantity, consumption value, and growth by regions, from 2019 to 2030.

Chapter 5 and 6, to segment the sales by Type and by Application, with sales market share and growth rate by Type, by Application, from 2019 to 2030.

Chapter 7, 8, 9, 10 and 11, to break the sales data at the country level, with sales quantity, consumption value, and market share for key countries in the world, from 2019 to 2024.and C-MET & HGF Inhibitors market forecast, by regions, by Type, and by Application, with sales and revenue, from 2025 to 2030.

Chapter 12, market dynamics, drivers, restraints, trends, and Porters Five Forces analysis.

Chapter 13, the key raw materials and key suppliers, and industry chain of C-MET & HGF Inhibitors.

Chapter 14 and 15, to describe C-MET & HGF Inhibitors sales channel, distributors, customers, research findings and conclusion.